Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $1.25, $0.08 worse than the analyst estimate of $1.33. Revenue for the quarter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE